Showing results (961-970 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|January 4, 2022
Ad-VT enhances the sensitivity of chemotherapy-resistant lung adenocarcinoma cells to gemcitabine and paclitaxel in vitro and in vivoGaojie Song, Chao Shang, Lili Sun, et al.
Investigational New Drugs|January 1, 1986
Phase I trial of intraperitoneal chemotherapy with 5-fluorouracil and citrovorum factorG T Budd, M J Schreiber, E Steiger, et al.
Investigational New Drugs|March 21, 2021
Significant benefit of everolimus in a patient with urothelial bladder cancer harboring a rare M1043I mutation of PIK3CAShouhua Pan, Si Li, Mingzhe Xiao, et al.
Investigational New Drugs|March 23, 2021
The clinical efficiency of TACE combined with simultaneous computed tomography-guided radiofrequency ablation for advanced hepatocellular carcinomaPeng Yuan, Fei Wang, Guangyu Zhu, et al.
Investigational New Drugs|September 14, 2011
Therapeutic reactivation of mutant p53 protein by quinazoline derivativesHamish S Sutherland, In Young Hwang, Elaine S Marshall, et al.
Investigational New Drugs|September 8, 2011
Cluvenone induces apoptosis via a direct target in mitochondria: a possible mechanism to circumvent chemo-resistance?Gianni Guizzunti, Emmanuel A Theodorakis, Alice L Yu, et al.
Investigational New Drugs|February 14, 2012
Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicitiesRoger B Cohen, Stéphane Oudard
Investigational New Drugs|February 3, 2012
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomasAngela Ruban, Tamara Berkutzki, Itzik Cooper, et al.
Investigational New Drugs|January 18, 2012
Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumorsToshiaki Takahashi, Narikazu Boku, Haruyasu Murakami, et al.
Investigational New Drugs|December 27, 2011
The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell linesHyun-Jin Nam, Hwang-Phill Kim, Young-Kwang Yoon, et al.
Pageof 372